Management of Stage II testicular seminoma over a period of 40 years

Beatrice Detti, Lorenzo Livi, Silvia Scoccianti, Mauro Gacci, Alberto Lapini, Tommaso Cai, Icro Meattini, Anna Maria Mileo, Alberto Iannalfi, Alessio Bruni, Giampaolo Biti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: To review the treatment, toxicity, and outcomes in patients with Stage II seminoma after orchidectomy. Materials and methods: A retrospective chart review of all patients with Stage II seminoma referred for initial treatment, from 1965 to 2005, was performed. Treatment approaches, toxicity, and outcomes were analyzed. Results: A total of 106 patients (83 with Stage IIA, 19 with Stage IIB, and 4 with Stage IIC) were seen between 1965 and 2005. Median age at diagnosis was 36 years (range: 19-71). Median follow-up was 21 years (range: 1.2-42). Eighty-nine patients were treated with adjuvant radiotherapy alone; 13 patients received a combined treatment modality with chemotherapy and radiotherapy after orchidectomy, 4 patients were treated with chemotherapy alone. Generally the treatment was well tolerated, with the main toxicity occurring in patients treated with extended-field radiotherapy. The 5-year disease-specific survival was 96% for the entire group. The 5-year relapse-free survivals for Stages IIA, IIB, and IIC disease were 94%, 72.5%, and 75%, respectively. Fifteen patients developed a relapse and were managed by chemotherapy; 5 of them achieved complete remission and remain free from further recurrence at last follow-up, while 10 died of the disease. Second malignancies were diagnosed in 4 (3.7%) patients during the follow-up. Conclusions: In Stage IIA seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone. Radiotherapy or chemotherapy should be offered as an alternative to Stage IIB patients. Chemotherapy remains the treatment of choice for Stage IIC seminoma.

Original languageEnglish
Pages (from-to)534-538
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume27
Issue number5
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Seminoma
Drug Therapy
Radiotherapy
Orchiectomy
Recurrence
Therapeutics
Adjuvant Radiotherapy
Survival
Second Primary Neoplasms

Keywords

  • Chemotherapy
  • Outcome
  • Radiotherapy
  • Stage II
  • Testicular seminoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Management of Stage II testicular seminoma over a period of 40 years. / Detti, Beatrice; Livi, Lorenzo; Scoccianti, Silvia; Gacci, Mauro; Lapini, Alberto; Cai, Tommaso; Meattini, Icro; Mileo, Anna Maria; Iannalfi, Alberto; Bruni, Alessio; Biti, Giampaolo.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 27, No. 5, 09.2009, p. 534-538.

Research output: Contribution to journalArticle

Detti, B, Livi, L, Scoccianti, S, Gacci, M, Lapini, A, Cai, T, Meattini, I, Mileo, AM, Iannalfi, A, Bruni, A & Biti, G 2009, 'Management of Stage II testicular seminoma over a period of 40 years', Urologic Oncology: Seminars and Original Investigations, vol. 27, no. 5, pp. 534-538. https://doi.org/10.1016/j.urolonc.2008.07.034
Detti, Beatrice ; Livi, Lorenzo ; Scoccianti, Silvia ; Gacci, Mauro ; Lapini, Alberto ; Cai, Tommaso ; Meattini, Icro ; Mileo, Anna Maria ; Iannalfi, Alberto ; Bruni, Alessio ; Biti, Giampaolo. / Management of Stage II testicular seminoma over a period of 40 years. In: Urologic Oncology: Seminars and Original Investigations. 2009 ; Vol. 27, No. 5. pp. 534-538.
@article{bf88535140eb4af194898a387229456e,
title = "Management of Stage II testicular seminoma over a period of 40 years",
abstract = "Objectives: To review the treatment, toxicity, and outcomes in patients with Stage II seminoma after orchidectomy. Materials and methods: A retrospective chart review of all patients with Stage II seminoma referred for initial treatment, from 1965 to 2005, was performed. Treatment approaches, toxicity, and outcomes were analyzed. Results: A total of 106 patients (83 with Stage IIA, 19 with Stage IIB, and 4 with Stage IIC) were seen between 1965 and 2005. Median age at diagnosis was 36 years (range: 19-71). Median follow-up was 21 years (range: 1.2-42). Eighty-nine patients were treated with adjuvant radiotherapy alone; 13 patients received a combined treatment modality with chemotherapy and radiotherapy after orchidectomy, 4 patients were treated with chemotherapy alone. Generally the treatment was well tolerated, with the main toxicity occurring in patients treated with extended-field radiotherapy. The 5-year disease-specific survival was 96{\%} for the entire group. The 5-year relapse-free survivals for Stages IIA, IIB, and IIC disease were 94{\%}, 72.5{\%}, and 75{\%}, respectively. Fifteen patients developed a relapse and were managed by chemotherapy; 5 of them achieved complete remission and remain free from further recurrence at last follow-up, while 10 died of the disease. Second malignancies were diagnosed in 4 (3.7{\%}) patients during the follow-up. Conclusions: In Stage IIA seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone. Radiotherapy or chemotherapy should be offered as an alternative to Stage IIB patients. Chemotherapy remains the treatment of choice for Stage IIC seminoma.",
keywords = "Chemotherapy, Outcome, Radiotherapy, Stage II, Testicular seminoma",
author = "Beatrice Detti and Lorenzo Livi and Silvia Scoccianti and Mauro Gacci and Alberto Lapini and Tommaso Cai and Icro Meattini and Mileo, {Anna Maria} and Alberto Iannalfi and Alessio Bruni and Giampaolo Biti",
year = "2009",
month = "9",
doi = "10.1016/j.urolonc.2008.07.034",
language = "English",
volume = "27",
pages = "534--538",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Management of Stage II testicular seminoma over a period of 40 years

AU - Detti, Beatrice

AU - Livi, Lorenzo

AU - Scoccianti, Silvia

AU - Gacci, Mauro

AU - Lapini, Alberto

AU - Cai, Tommaso

AU - Meattini, Icro

AU - Mileo, Anna Maria

AU - Iannalfi, Alberto

AU - Bruni, Alessio

AU - Biti, Giampaolo

PY - 2009/9

Y1 - 2009/9

N2 - Objectives: To review the treatment, toxicity, and outcomes in patients with Stage II seminoma after orchidectomy. Materials and methods: A retrospective chart review of all patients with Stage II seminoma referred for initial treatment, from 1965 to 2005, was performed. Treatment approaches, toxicity, and outcomes were analyzed. Results: A total of 106 patients (83 with Stage IIA, 19 with Stage IIB, and 4 with Stage IIC) were seen between 1965 and 2005. Median age at diagnosis was 36 years (range: 19-71). Median follow-up was 21 years (range: 1.2-42). Eighty-nine patients were treated with adjuvant radiotherapy alone; 13 patients received a combined treatment modality with chemotherapy and radiotherapy after orchidectomy, 4 patients were treated with chemotherapy alone. Generally the treatment was well tolerated, with the main toxicity occurring in patients treated with extended-field radiotherapy. The 5-year disease-specific survival was 96% for the entire group. The 5-year relapse-free survivals for Stages IIA, IIB, and IIC disease were 94%, 72.5%, and 75%, respectively. Fifteen patients developed a relapse and were managed by chemotherapy; 5 of them achieved complete remission and remain free from further recurrence at last follow-up, while 10 died of the disease. Second malignancies were diagnosed in 4 (3.7%) patients during the follow-up. Conclusions: In Stage IIA seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone. Radiotherapy or chemotherapy should be offered as an alternative to Stage IIB patients. Chemotherapy remains the treatment of choice for Stage IIC seminoma.

AB - Objectives: To review the treatment, toxicity, and outcomes in patients with Stage II seminoma after orchidectomy. Materials and methods: A retrospective chart review of all patients with Stage II seminoma referred for initial treatment, from 1965 to 2005, was performed. Treatment approaches, toxicity, and outcomes were analyzed. Results: A total of 106 patients (83 with Stage IIA, 19 with Stage IIB, and 4 with Stage IIC) were seen between 1965 and 2005. Median age at diagnosis was 36 years (range: 19-71). Median follow-up was 21 years (range: 1.2-42). Eighty-nine patients were treated with adjuvant radiotherapy alone; 13 patients received a combined treatment modality with chemotherapy and radiotherapy after orchidectomy, 4 patients were treated with chemotherapy alone. Generally the treatment was well tolerated, with the main toxicity occurring in patients treated with extended-field radiotherapy. The 5-year disease-specific survival was 96% for the entire group. The 5-year relapse-free survivals for Stages IIA, IIB, and IIC disease were 94%, 72.5%, and 75%, respectively. Fifteen patients developed a relapse and were managed by chemotherapy; 5 of them achieved complete remission and remain free from further recurrence at last follow-up, while 10 died of the disease. Second malignancies were diagnosed in 4 (3.7%) patients during the follow-up. Conclusions: In Stage IIA seminoma, radiotherapy continues to provide excellent results, as the majority of patients will be cured with this treatment alone. Radiotherapy or chemotherapy should be offered as an alternative to Stage IIB patients. Chemotherapy remains the treatment of choice for Stage IIC seminoma.

KW - Chemotherapy

KW - Outcome

KW - Radiotherapy

KW - Stage II

KW - Testicular seminoma

UR - http://www.scopus.com/inward/record.url?scp=69249107403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249107403&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2008.07.034

DO - 10.1016/j.urolonc.2008.07.034

M3 - Article

C2 - 18848787

AN - SCOPUS:69249107403

VL - 27

SP - 534

EP - 538

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 5

ER -